Scarica l'app Stockscreener
3.845
3.25%
0.145
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.70
Aprire:
$3.86
Volume 24 ore:
592.74K
Relative Volume:
0.09
Capitalizzazione di mercato:
$912.72M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-1.8137
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
-5.44%
1M Prestazione:
+4.37%
6M Prestazione:
+232.18%
1 anno Prestazione:
+73.64%
Intervallo 1D:
$3.7701
$3.8899
Intervallo di 1 settimana:
$3.66
$4.01
Portata 52W:
$0.6925
$4.13
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.85 | 877.16M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
125.17 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.61 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.03 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.96 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
485.41 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-25 | Iniziato | Piper Sandler | Overweight |
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Is Esperion Therapeutics Inc a good long term investmentGlobal Trade Effects & Free Rapid Wealth Building - earlytimes.in
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 4.8%Time to Sell? - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
PFE6265887 Bond Coupon Analysis — Rate & Payments - TradingView — Track All Markets
Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week HighTime to Buy? - MarketBeat
Is Esperion Therapeutics Inc. stock attractive for long term wealth buildingPortfolio Update Summary & Real-Time Volume Triggers - Улправда
Will Esperion Therapeutics Inc. stock split attract more investorsJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - DonanımHaber
How Esperion Therapeutics Inc. (0ET) stock compares with top peersQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - DonanımHaber
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes - The Manila Times
Esperion's Bempedoic Acid Recognized by ACC as Effective LDL-C Lowering Therapy for Patients with PAD and Diabetes - Quiver Quantitative
Esperion’s Bempedoic Acid Receives Recommendation in 2025 - GlobeNewswire
Take Profit: Will Esperion Therapeutics Inc. stock maintain momentum in 2025 - DonanımHaber
New pill cuts serious limb risks for diabetics with artery disease, ACC says - Stock Titan
Can Esperion Therapeutics Inc. stock hit record highs againJuly 2025 Macro Moves & AI Powered Market Entry Strategies - Улправда
Esperion Therapeutics Q3 2025 Earnings Preview - MSN
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity - Stock Titan
Esperion Therapeutics (ESPR) CEO files Form 4 for 48,244-share tax sale - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $23,917.39 in Stock - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) CFO Benjamin Halladay Sells 7,337 Shares - MarketBeat
Esperion Therapeutics Executives Sell Shares to Satisfy Tax Obligations - TradingView — Track All Markets
CFO Halladay Surrenders 7,337 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets
Esperion Therapeutics (ESPR) CFO reports 7,337-share sale for tax obligations - Stock Titan
Aug Macro: Will Esperion Therapeutics Inc. (0ET) stock outperform value peers2025 EndofYear Setup & Community Verified Swing Trade Signals - ulpravda.ru
Officer Looker Files To Sell 6,517 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets
PFE6265887 Bond Analysis — Key Metrics - TradingView — Track All Markets
Investors Purchase High Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month HighShould You Buy? - MarketBeat
Esperion’s Stock Surge: Opportunity Knocks? - StocksToTrade
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results - Yahoo Finance
Esperion announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Esperion Grants Stock Options and RSUs to New Chief Commercial Officer and Employees - Quiver Quantitative
Esperion Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Two Seas Capital LP Raises Holdings in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Will Esperion Therapeutics Inc. (0ET) stock enhance shareholder valueEarnings Overview Summary & Smart Money Movement Alerts - Newser
Esperion stock hits fair value target with 77% gain since April 2024 - Investing.com Australia
Esperion Therapeutics, Inc.Common Stock (Nasdaq:ESPR) Stock Quote - Markets Financial Content
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Esperion Therapeutics Inc. (0ET) stock a top dividend aristocrat candidateTrend Reversal & Stepwise Trade Execution Plans - Newser
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Trading 6% HigherHere's What Happened - MarketBeat
Esperion a new overweight at Piper Sandler on CV franchise - MSN
Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler - MarketBeat
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
Esperion Therapeutics: Soaring Momentum Observed - StocksToTrade
Piper Sandler Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - Nasdaq
Piper Sandler initiates Esperion Therapeutics stock with Overweight rating By Investing.com - Investing.com South Africa
Esperion’s Strategic Moves: What It Means? - StocksToTrade
Esperion Therapeutics Shares Rise After Piper Sandler Initiates Coverage - marketscreener.com
Esperion Stock Grows Amid Promising Japanese Partnership and Q3 Earnings - timothysykes.com
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):